Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-1.33 Insider Own0.10% Shs Outstand194.68M Perf Week-7.58%
Market Cap640.50M Forward P/E- EPS next Y-1.29 Insider Trans8.35% Shs Float179.97M Perf Month-48.59%
Income-244.80M PEG- EPS next Q-0.37 Inst Own79.40% Short Float27.61% Perf Quarter-59.63%
Sales31.30M P/S20.46 EPS this Y-44.60% Inst Trans-10.94% Short Ratio9.02 Perf Half Y-39.41%
Book/sh0.36 P/B9.14 EPS next Y14.60% ROA-42.00% Target Price7.13 Perf Year-30.59%
Cash/sh1.31 P/C2.51 EPS next 5Y- ROE-150.50% 52W Range3.02 - 8.41 Perf YTD-46.33%
Dividend- P/FCF- EPS past 5Y2.90% ROI-48.50% 52W High-60.88% Beta2.40
Dividend %- Quick Ratio3.00 Sales past 5Y-23.30% Gross Margin96.50% 52W Low8.94% ATR0.31
Employees227 Current Ratio3.00 Sales Q/Q-44.90% Oper. Margin- RSI (14)24.69 Volatility7.22% 6.90%
OptionableYes Debt/Eq5.25 EPS Q/Q-35.70% Profit Margin- Rel Volume0.49 Prev Close3.32
ShortableYes LT Debt/Eq5.07 EarningsMay 05 Payout- Avg Volume5.51M Price3.29
Recom2.30 SMA20-20.43% SMA50-43.23% SMA200-42.12% Volume2,688,100 Change-0.90%
07-Feb-14Reiterated Stifel Buy $9 → $11
21-Jan-14Reiterated Maxim Group Buy $7.50 → $11
12-Nov-13Upgrade Maxim Group Hold → Buy $7.50
28-May-13Downgrade Maxim Group Buy → Hold $35 → $35
30-Nov-12Reiterated Stifel Nicolaus Buy $8 → $9
20-Apr-12Initiated Maxim Group Buy $9
15-Mar-12Resumed Stifel Nicolaus Buy $8
17-Aug-11Initiated Stifel Nicolaus Hold $8
18-Nov-09Downgrade Merriman Buy → Neutral
17-Jun-09Initiated Boenning & Scattergood Neutral
15-Dec-08Reiterated Lazard Capital Buy $7 → $8
24-Nov-08Reiterated Lazard Capital Buy $7
16-Oct-08Initiated Merriman Curhan Ford Buy
14-Aug-08Initiated Banc of America Sec Neutral $7
06-Aug-08Reiterated Lazard Capital Buy $12 → $10
06-Aug-08Downgrade Canaccord Adams Buy → Hold
08-Jul-08Initiated Canaccord Adams Buy $7.30
07-Dec-07Reiterated Fortis Bank Hold $10 → $9
14-Sep-07Initiated Lazard Capital Buy $14
04-Sep-07Downgrade Wachovia Outperform → Mkt Perform
19-Apr-14 06:31PM  1 of These 3 Cratering Biotechs is a Buy at Motley Fool
09-Apr-14 06:00AM  3 Stocks Under $10 to Trade for Breakouts at TheStreet
04-Apr-14 12:05PM  Why I Bought Exelixis at Motley Fool
09:02AM  Morning Movers in Biotech: Celgene Corporation, Mylan, Inc. and Exelixis, Inc. at Motley Fool
06:18AM  Piper says time to buy shares of Exelixis theflyonthewall.com
03-Apr-14 09:31AM  Are These 3 Biotechs Bad News Buys? at Motley Fool
31-Mar-14 07:43PM  Exelixis Continues On at Motley Fool
03:21PM  Why Red Hat, Caesars Entertainment, and Exelixis Tumbled Today at Motley Fool
03:20PM  Which Biotech Blow-Up Is a Bad-News Buy? at Motley Fool
29-Mar-14 08:01AM  3 Horrendous Health-Care Stocks This Week at Motley Fool
28-Mar-14 09:31AM  Exelixis Inc's Comet Fails To Dazzle at Motley Fool -12.44%
07:00AM  Is This the Year Exelixis Excels? Morningstar
27-Mar-14 06:04PM  Nasdaq stocks posting largest volume increases AP
06:03PM  Most active Nasdaq-traded stocks AP
01:44PM  Most active Nasdaq-traded stocks AP
09:45AM  Trade-Ideas: Exelixis (EXEL) Is Today's "Dead Cat Bounce" Stock at TheStreet
26-Mar-14 07:33PM  Talk About High Clinical Trial Expectations at Motley Fool -39.29%
07:01PM  Why Exelixis, Inc., Plug Power Inc., and King Digital Entertainment PLC Are Today's 3 Worst Stocks at Motley Fool
06:04PM  Nasdaq stocks posting largest volume increases AP
06:04PM  Most active Nasdaq-traded stocks AP
04:48PM  EXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online
03:18PM  Exelixis Plunges Most Since 2011 as Drug Trial Continues at Bloomberg
02:43PM  Biotechs still sliding, but Wall Street says don't hit panic button just yet at MarketWatch
01:16PM  Most active Nasdaq-traded stocks AP
12:19PM  On The Fly: Midday Wrap at theflyonthewall.com
12:05PM  Exelixis Enters the Danger Zone at 24/7 Wall St.
11:42AM  Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis at TheStreet
09:13AM  Todays Top Biotech Stories: Insmed, Exelixis, United Therapeutics, and Alnylam at Motley Fool
25-Mar-14 07:17PM  Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men with Metastatic Castration-Resistant Prostate Cancer Business Wire
04:31PM  EXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online
10:11AM  4 Reasons To Be Bullish On Exelixis In The Near Term at Seeking Alpha
09:25AM  Todays Top Biotech Stories: Halozyme, Exelixis, and VIVUS at Motley Fool
07:09AM  Exelixis announces Cometriq approved in Europe theflyonthewall.com
07:03AM  Cometriq® approved in Europe for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. Thomson Reuters ONE
06:00AM  Exelixis Receives Approval for COMETRIQ® (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma Business Wire
24-Mar-14 07:53PM  1 Piece of News That Could Move Exelixis at Motley Fool
11-Mar-14 06:14AM  Traders turning bullish on Exelixis optionMONSTER
06:14AM  Traders turning bullish on Exelixis
28-Feb-14 05:24PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
26-Feb-14 07:56PM  Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care Conference Business Wire
07:56PM  Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care Conference
01:04PM  EXELIXIS, INC. Financials EDGAR Online Financials
21-Feb-14 05:15PM  EXELIXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
11:04AM  Exelixis Q4 Loss In Line with Expectations Zacks
11:04AM  Exelixis Q4 Loss In Line with Expectations
20-Feb-14 11:37PM  Exelixis CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
11:37PM  Exelixis CEO Discusses Q4 2013 Results - Earnings Call Transcript
05:29PM  Exelixis' Q4 Loss Widens as Investors Await Key Trial Data at Motley Fool
05:00PM  Exelixis, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN
04:55PM  Exelixis, Inc. Discusses Q4 2013 Results (Webcast) at Seeking Alpha
04:55PM  Exelixis, Inc. Discusses Q4 2013 Results (Webcast)
04:33PM  Exelixis sees no significant contract and license revenue in 2014 theflyonthewall.com
04:18PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:15PM  Exelixis Announces Fourth Quarter and Full Year 2013 Financial Results Business Wire
04:03PM  EXELIXIS, INC. Files SEC form 10-K, Annual Report EDGAR Online
07:34AM  Exelixis, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN
07:07AM  Q4 2013 Exelixis, Inc. Earnings Release - After Market Close CCBN
12-Feb-14 05:28PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
05:26PM  Exelixis Appoints Executive Vice President and General Counsel Business Wire
10-Feb-14 04:35PM  Exelixis Announces February 20th Webcast of Fourth Quarter and Full Year 2013 Financial Results Conference Call Business Wire
06-Feb-14 02:02AM  3 Stocks to Get on Your Watchlist at Motley Fool
31-Jan-14 05:48PM  Exelixis Announces Webcasts of Investor Conference Presentations in February Business Wire
05:48PM  Exelixis Announces Webcasts of Investor Conference Presentations in February
23-Jan-14 05:11PM  EXELIXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
05:11PM  EXELIXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:33AM  Exelixis Announces Pricing of Overnight Offering of 10,000,000 Shares of Common Stock Business Wire
08:33AM  Exelixis Announces Pricing of Overnight Offering of 10,000,000 Shares of Common Stock
22-Jan-14 04:02PM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligat EDGAR Online
04:02PM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligat
04:00PM  Exelixis Launches Proposed Overnight Public Offering of Common Stock Business Wire
04:00PM  Exelixis Launches Proposed Overnight Public Offering of Common Stock
06:19AM  [$$] Exelixis Has an Excellent Outlook at Barrons.com
06:19AM  [$$] Exelixis Has an Excellent Outlook
21-Jan-14 03:38AM  Intercept Pharmaceuticals: 6 Different Insiders Have Sold Shares This Year at Seeking Alpha
17-Jan-14 06:30PM  3 Reasons Exelixis Could Excel in 2014 at Motley Fool
06:30PM  3 Reasons Exelixis Could Excel in 2014
06:34AM  Cramer's Lightning Round - Stratasys Is The Best In The Group (1/16/14) at Seeking Alpha
06:00AM  'Mad Money' Lightning Round: Home Depot Beats Lowe's at TheStreet
16-Jan-14 06:36PM  Lightning Round: Disney, Lowe's & More at CNBC
15-Jan-14 10:25PM  Exelixis's CEO Presents at 32nd JPMorgan Healthcare Conference (Transcript) at Seeking Alpha
10:25PM  Exelixis's CEO Presents at 32nd JPMorgan Healthcare Conference (Transcript)
14-Jan-14 01:39PM  [video] Exelixis CEO: 30,000 men will die of prostate cancer this year at CNBC
01:39PM  [video] Exelixis CEO: 30,000 men will die of prostate cancer this year
10-Jan-14 09:05AM  Scorching Hot Biotech Tape: Small-Cap and Mid-Cap Stocks on Fire at 24/7 Wall St.
09:05AM  Scorching Hot Biotech Tape: Small-Cap and Mid-Cap Stocks on Fire
06:00AM  Biotech Stock Mailbag: NeoStem, MannKind, Inovio at TheStreet
06:00AM  Biotech Stock Mailbag: NeoStem, MannKind, Inovio
09-Jan-14 02:08PM  Intercept Pharmaceuticals: Study Success Paves Way to Multi-Billion Market at Barrons.com
10:39AM  Intercept Pharmaceuticals: Study Success Points to Multi-Billion Market at Barrons.com
07-Jan-14 06:45AM  Exelixis (EXEL) Jumps: Stock Moves 11.1% Higher Zacks
06:45AM  Exelixis (EXEL) Jumps: Stock Moves 11.1% Higher
06-Jan-14 05:21PM  Exelixis Has A Stellar Year Ahead at Seeking Alpha +11.09%
05:21PM  Exelixis Has A Stellar Year Ahead
06:37AM  Exelixis upgraded to Overweight from Neutral at Piper Jaffray theflyonthewall.com
06:37AM  Exelixis upgraded to Overweight from Neutral at Piper Jaffray
03-Jan-14 08:00AM  Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular at TheStreet
20-Dec-13 05:01PM  EXELIXIS, INC. Files SEC form 8-K, Other Events EDGAR Online
05:01PM  EXELIXIS, INC. Files SEC form 8-K, Other Events
19-Dec-13 04:21PM  COMETRIQ® (cabozantinib) Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma Business Wire
04:21PM  COMETRIQ® (cabozantinib) Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaEVP and Chief Medical OfficerFeb 15Option Exercise0.002,188071,494Feb 18 09:30 PM
KARBE FRANKEVP and CFOFeb 15Option Exercise0.001,954094,847Feb 18 09:31 PM
Lamb PeterEVP, Discovery Research & CSOFeb 15Option Exercise0.003,126035,743Feb 18 09:27 PM
SIMONTON PAMELA AEVP, ExelixisFeb 15Option Exercise0.001,875019,014Feb 18 09:28 PM
MORRISSEY MICHAELPresident and CEOFeb 15Option Exercise0.003,12503,125Feb 18 09:28 PM
SIMONTON PAMELA AEVP and General CounselNov 15Option Exercise0.001,875017,843Nov 15 09:22 PM
KARBE FRANKEVP and CFONov 15Option Exercise0.001,953093,626Nov 15 09:20 PM
Lamb PeterEVP, Discovery Research & CSONov 15Option Exercise0.005,208034,181Nov 15 09:21 PM
MORRISSEY MICHAELPresident and CEONov 15Option Exercise0.003,12503,125Nov 15 09:21 PM
Schwab GiselaEVP and Chief Medical OfficerNov 15Option Exercise0.005,312070,480Nov 15 09:21 PM
WILLSEY LANCEDirectorAug 29Buy5.1510,00051,454333,700Aug 30 06:44 PM
Schwab GiselaEVP and Chief Medical OfficerAug 15Option Exercise0.002,188066,791Aug 16 05:36 PM
Lamb PeterEVP, Discovery Research & CSOAug 15Option Exercise0.003,125030,538Aug 16 05:36 PM
MORRISSEY MICHAELPresident and CEOAug 15Option Exercise0.003,12503,125Aug 16 05:35 PM
KARBE FRANKEVP and CFOAug 15Option Exercise0.001,953091,248Aug 16 05:24 PM
SIMONTON PAMELA AEVP and General CounselAug 15Option Exercise0.001,875016,672Aug 16 05:20 PM
MORRISSEY MICHAELPresident and CEOMay 15Option Exercise0.003,12504,817May 17 07:21 PM
Lamb PeterEVP, Discovery Research & CSOMay 15Option Exercise0.003,124028,589May 17 07:17 PM
KARBE FRANKEVP and CFOMay 15Option Exercise0.001,953090,030May 17 07:17 PM
SIMONTON PAMELA AEVP and General CounselMay 15Option Exercise0.001,875015,503May 17 07:16 PM
Schwab GiselaEVP and Chief Medical OfficerMay 15Option Exercise0.002,187065,427May 17 07:17 PM